Review Article
Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma
Table 2
Summary of novel immunotherapeutic strategies for melanoma patients.
| Target | Therapeutic strategy | Reference |
| Topoisomerase I | Topoisomerase I inhibitor + anti-PD-L1 or anti-PD1 mAbs | [79] | Polypeptide gp75 | Anti gp75 mAb + anti-PD1 mAb | [81] | Histone deacetylase (HDAC) | Pan-HDAC inhibitors + anti-PD1 mAb | [82] | Fas | Fas/Fas-ligand blocking mAbs | [83] | CD40 | Anti-CD40 mAb + CpG ODNs | [84] | CTLA-4 and GD2 | Anti-CTL-A4 mAb + anti-GD2 mAb conjugated with IL-2 | [84] | Regulatory cells | Foxp3 DNA/recombinant protein vaccine | [85] | GP33-41 antigen | Adenoviral vector expressing GP33-41 tumor-associated antigen | [86] | Unknown | Docetaxel + adoptive T cell transfer + DC immunotherapy | [93] | MART-1 | MART-1-specific CD8+ T cells | [94] |
|
|